APA (7th ed.) Citation

X, L., P, W., & G, L. (2025). NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(4), 1529. https://doi.org/10.1007/s12094-024-03735-7

Chicago Style (17th ed.) Citation

X, Liu, Wang P, and Liu G. "NRI and SIRI Are the Optimal Combinations for Prognostic Risk Stratification in Patients with Non-small Cell Lung Cancer After EGFR-TKI Therapy." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 27, no. 4 (2025): 1529. https://doi.org/10.1007/s12094-024-03735-7.

MLA (9th ed.) Citation

X, Liu, et al. "NRI and SIRI Are the Optimal Combinations for Prognostic Risk Stratification in Patients with Non-small Cell Lung Cancer After EGFR-TKI Therapy." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 27, no. 4, 2025, p. 1529, https://doi.org/10.1007/s12094-024-03735-7.